Advertisement
Document › Details
Immunicum AB. (2/3/17). "Press Release: Immunicum AB CEO to present at BIO CEO & Investor Conference". Gothenburg.
Immunicum AB (publ; First North Premier: IMMU.ST) a biopharmaceutical company advancing a novel immuno-oncology treatment against a range of solid tumors, today announced that Carlos de Sousa, MD, CEO of Immunicum, will present at the BIO CEO & Investor Conference which will be held February 13-14, 2017 at the Waldorf Astoria, New York, NY.
Presentation Information:
Date: Monday, February 13, 2017
Time: 5:00 PM EST
Presentation Room: Duke of Windsor
For more information, please contact
Carlos de Sousa, CEO, Immunicum
Ph: +46 (0) 31 41 50 52
E-mail: info@immunicum.com
About Immunicum AB (publ)
Immunicum AB (First North Premier: IMMU.ST) is a clinical stage company developing novel immuno-oncology therapies against a range of solid tumors. The Company's lead compound, INTUVAX® is currently being evaluated in clinical trials for the treatment of kidney cancer, liver cancer and gastrointestinal stromal tumors. INTUVAX® was designed to combine the best of two worlds: a cost-effective cell-based (allogeneic) and off-the-shelf therapy that is capable of triggering a highly personalized and potentially long-lasting immune response against tumor cells throughout the body. www.immunicum.com
The Company's Certified Adviser is Redeye AB
Ph: + 46 8 545 013 31
www.redeye.se
Record changed: 2023-06-05 |
Advertisement
More documents for Mendus (Group)
- [1] Immunicum AB. (8/22/17). "Press Release: Immunicum AB (publ) Announces Upcoming Presentations at Conferences in August and September"....
- [2] Immunicum AB. (8/18/17). "Press Release: Interim Report Q2 – Corporate Update and Outlook"....
- [3] Immunicum AB. (2/17/17). "Press Release: Year-end Report 2016 (July 2016 – December 2016)". Gothenburg....
- [4] Immunicum AB. (2/13/17). "Press Release: Immunicum AB Appoints Karin Hoogendoorn as Head of CMC". Gothenburg....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement
» top